Long-term use of PCSK9i reduces CV events in ASCVD
This video was recorded during the ESC Congress 2022 in Barcelona, Spain.
Michelle O'Donoghue, MD is a cardiovascular medicine specialist at Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School, Boston, MA, USA.
This recording was developed under auspices of EPCCS. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of EPCCS.
Read our summary of this analysis
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: